Patty Diez

We support #WorldRTDay and the multiprofession approach to high quality #clinicaltrials leading to improved treatment and outcomes for our patients #WRAD

Current vacancies – East and North Hertfordshire NHS Trust Are you a retired NHS employee? You could join the NHS Retirement Fellowship.

Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring!

Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding:

www.enherts-tr.nhs.uk/careers/vaca...

Deadline 18th August.

DM for further information. #medphys #rtt #rtqa

A really educational day. Big shoutout to Tom Rackley & Rebecca Muirhead for leading the event & superstars @alison-tree.bsky.social and Dione Lother for sharing their wisdom. Amazing practical insights from @aileenduffton.bsky.social @marina-khan.bsky.social Helen Grimes & Joe Flaherty. Congrats!

📢The joint #CallForAbstracts with
@TheLancetOncol
& Radiotherapy & Oncology led to 3,485 clinical abstracts at #ESTRO25 – the highest ever!
📍Up next:: #ESTRO26 in Stockholm with a dedicated clinical trials session!
ℹ️https://bit.ly/4leXqTY
#Radonc

🧠📸 Proud to represent RTTs as part of the 2022 ESTRO Physics Workshop IGRT Working Group! Our expert consensus on optimising CBCT doses for IGRT is now available.

🔗 doi.org/10.1016/j.ra...

#MedPhysics #Radiotherapy #IGRT #ESTRO2022 #MedicalImaging #RadiationOncology #RTT

@uksabr.bsky.social is coming to Newcastle!
Save the dates: Annual Professional Conference and pre-conference lung workshop. Wed 19, Thurs 20 & Fri 21 Nov. More details bit.ly/3Zh2YVj - there is no other event like it. @gerryhanna.bsky.social @drpeedell.bsky.social @marina-khan.bsky.social

A great opportunity to work in cutting edge #clinicaltrials within a fun multidisciplinary team @notchonctrainees.bsky.social

What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!

Don’t forget to register for the annual UK Oncology forum, which is FREE to attend. Breakout sessions covering topics including prostate cancer and radiotherapy, including Dr Ben O’Leary @icr.ac.uk, Dr Rovel Colaco, Dr Katie Spencer and Prof Stefanie Corradini oncology-forum.co.uk/register/

Congratulations Liz on your interdisciplinary award👏🏽🥳 @rttqa.bsky.social _UK does an incredible job ensuring that #radiotherapy is robust. Fantastic leadership! @nhsengland.bsky.social #ESTRO25

Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!

Dr Murray Brunt presents the excellent 10y results of the FAST-FORWARD #breast cancer trial. A pleasure to have contributed to this practice-changing #clinicaltrial
@nihr.bsky.social @icr-ctsu.bsky.social

Amazing work Rita. We anticipate the publication!

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship …

Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres
www.sciencedirect.com/science/arti...

#NOTCH2025

✅ Quality Assurance is key in clinical trials, yet often overlooked! Dr. Sarah Gwynne SW Wales Cancer Centre (@rttqa.bsky.social) delivered an outstanding session on RT QA in the SCOPE trial

A fantastic deep dive into an essential aspect of oncology research 🎯

Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial Optimal management of oligoprogressive prostate cancer whilst on androgen receptor pathway inhibitors (ARPi) is not known. The **** trial tests the ro…

TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy.

www.sciencedirect.com/science/arti...

Great party @btog.bsky.social ! Have a great time… send some @drpeedell.bsky.social pics with the #POPGODS

Do you work on clinical trials?

We need your help to understand the challenges to designing & delivering greener trials. Only 30 responses so far but we can all have a say on this topic. Please take 10 minutes to tell us what you think tinyurl.com/GreenTrials

Please share across your networks

Ever wondered if urethral dose explained the differential GU toxicity by platform in PACE-B? It appears not- credit to Dr Ragu Ratnakumaran @ijrobp.bsky.social

eur01.safelinks.protection.outlook.com?url=https%3A...

Gyn-SMART - Upcoming events Gyn-SMART Winter Edition

Authors for recently published INTERLACE and A18 #cervix Ca trials present and discuss findings as well as results from the #EMBRACE team. Gyn-SMART - Webinar TODAY 4pm CET ⬇️ #radonc

sites.google.com/view/gyn-sma...

Hey Rad Onc community!

The Red Journal @ijrobp.bsky.social is calling for papers for a new special issue:

SBRT - From Clinical Trials to Your Clinic

Details below...⬇️⬇️⬇️

<em>Medical Physics</em> | AAPM Journal | Wiley Online Library Background The Joint AAPM-ESTRO TG-360 is developing a quantitative framework to evaluate treatment verification systems used for patient-specific quality assurance (PSQA). A subgroup was commission...

Which failures do patient-specific quality assurance (PSQA) systems need to catch?
First publication of an international collaboration systematically addressing PSQA in Radiation Therapy.

dx.doi.org/10.1002/mp.1...

Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.

Controversial paper just out in the @thelancet.bsky.social

Study of population-health impact of funding new drugs recommended by the NHS England’s NICE body during 2000–20:

➡️New drugs resulted cost £75·1 billion
➡️net loss of approximately 1·25 million QALYs

www.thelancet.com/journals/lan...

Great opportunity to shape the future of clinical oncology via the RCR by joining Faculty Board. Applications close Jan 5. rcr.ac.uk/elected-roles/…

The amazing @drdavidpalma.bsky.social reminding us that leaving mets untreated leads to poorer outcomes. SBRT must be driven by next gen imaging #UKSABRconsortium #medsky #radonc

Dr Harshani Green presenting her dosimetric work, testing whether Cyberknife, VMAT or protons are best for a treatment of RCC. Protons may have some dosimetric benefits for OARs @icrlondon.bsky.social #SABRconsortium #medsky

And we are off! Packed house for the 2024 #SABRconsortium, record numbers of delegates and stellar speakers including @drdavidpalma.bsky.social and Shankar Siva (still on the other platform). #medsky @drpeedell.bsky.social @gerryhanna.bsky.social

As well as possibly being more effective, 26 Gy in one fraction for RCC may preferentially spare normal
kidney tissue, minising effect on GFR #SABRconsortium #medsky #radonc

Masterclass from Professor Marcel van Herk @cruk-mi.bsky.social , starting with the famous/notorious (his words!) margin recipe that bears his name #medsky #SABRconsortium

Patty Diez showing the incredible amount of work RTTQA have done to accredit nearly all UK centres for SBRT 👏 #medsky #UKSABRconsortium